All In Biotech

NDA 210913 · Sun Pharm

Cequa

Cyclosporine · Ophthalmic · Calcineurin Inhibitor Immunosuppressant

Last checked: Nov 20, 2026Latest source record: Sep 20, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 14, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,166

250 Phase 3, 65 recruiting

FAERS reports

60,833

52,137 serious, 11,014 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 15, 2026.

CEQUA ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). ( 1 ) CEQUA ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye) ( 1 ).

Mechanism: Cyclosporine is a calcineurin inhibitor immunosuppressant agent when administered systemically. In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, topical administration of cyclosporine is thought to act as a partial immunomodulator. The exact mechanism of action is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 14, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • CEQUA · CYCLOSPORINE 0.09% · SOLUTION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective8,262
  • off label use7,937
  • product use in unapproved indication3,648
  • pyrexia2,809
  • diarrhoea2,261
  • condition aggravated2,214
  • nausea2,087
  • pneumonia2,006
  • cytomegalovirus infection1,948
  • eye irritation1,799
  • headache1,761
  • fatigue1,757

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004881
2005900
20061,029
2007984
20081,675
20091,917
20101,635
20112,284
20121,609
2013734
2014794
2015764
2016955
20171,235
20181,752
20192,446
20204,018
20213,913
20225,615
20235,816
20248,274
20256,872
20264,725

Recalls

4 FDA enforcement reports for this application.

  • Sep 7, 2023 · Class III · Terminated

    Subpotent: Out of Specification result observed for low assay

  • Apr 1, 2022 · Class III · Terminated

    Subpotent Drug and Presence of Particulate Matter: low out-of-specification results obtained for assay and the presence of particulate matter.

  • May 7, 2021 · Class III · Terminated

    Subpotent and Presence of Particulates .

  • Feb 22, 2021 · Class III · Terminated

    Subpotent

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cequa (Cyclosporine)

2024 spending

$76.6M

Beneficiaries

34,287

90,056 claims

Per beneficiary

$2,233

$9.34 per unit

View as table
YearSpending
2020$17,986,575
2021$49,318,764
2022$59,466,260
2023$65,658,118
2024$76,559,259

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,031 on PubMed

Sponsor: Sun Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.